| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Comprehensive income (loss) | 25,464 | -12,724 | -41,989 | -54,193 |
| Net income (loss) per common share, basic (in dollars per share) | 0.29 | -0.14 | -0.47 | -0.7 |
| Net income (loss) per common share, diluted (in dollars per share) | 0.28 | -0.14 | -0.47 | -0.7 |
| Weighted average common shares outstanding, basic (in shares) | 89,230,420 | 88,945,624 | 88,355,973 | 77,779,379 |
| Weighted average common shares outstanding, diluted (in shares) | 102,618,560 | 88,945,624 | 88,355,973 | 77,779,379 |
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)